198th ENMC International Workshop: 7th Workshop on Centronuclear (Myotubular) myopathies, 31st May - 2nd June 2013, Naarden, The Netherlands

Neuromuscular Disorders

Volumn 23, Issue 12, 2013, Pages 1033-1043

  Jungbluth, Heinz ^a,b,c   Wallgren Pettersson, Carina ^d,e   Laporte, Jocelyn F ^f,g,h,i,j  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF HELSINKI   (Finland)

^e FOLKHÄLSAN RESEARCH CENTER   (Finland)

^f INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^g INSERM   (France)

^h CNRS   (France)

ⁱ UNIVERSITÉ DE STRASBOURG   (France)

^j Chaire de Génétique Humaine   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

3E10 ANTIBODY; ANTIBODY; EDROPHONIUM CHLORIDE; MYOTUBULARIN; PARVOVIRUS VECTOR; PHOSPHATASE; PYRIDOSTIGMINE; UNCLASSIFIED DRUG;

ARTICLE; CENTRONUCLEAR MYOPATHY; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DISEASE REGISTRY; GENE MUTATION; GENE SEQUENCE; GENE THERAPY; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; HUMAN; NETHERLANDS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; WORKSHOP;

GENOTYPE; HUMANS; INTERNATIONAL COOPERATION; MYOPATHIES, STRUCTURAL, CONGENITAL; NETHERLANDS; PHENOTYPE;

EID: 84888428876     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2013.08.006     Document Type: Article

References (67)

1. Jungbluth H., Wallgren-Pettersson C., Laporte J.F. 164th ENMC International workshop: 6th workshop on centronuclear (myotubular) myopathies, 16-18th January 2009, Naarden, The Netherlands. Neuromuscul Disord 2009, 19:721-729.
2. Romero N.B. Centronuclear myopathies: a widening concept. Neuromuscul Disord 2010, 20:223-228.
3. Bohm J., Yis U., Ortac R., et al. Case report of intrafamilial variability in autosomal recessive centronuclear myopathy associated to a novel BIN1 stop mutation. Orphanet J Rare Dis 2010, 5:35.
4. Susman RD, Quijano-Roy S, Yang N, et al. Expanding the clinical, pathological and MRI phenotype of DNM2-related centronuclear myopathy. 2010;20:229-37.
5. Bohm J., Biancalana V., Dechene E.T., et al. Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy. Hum Mutat 2012, 33:949-959.
6. Biancalana V., Beggs A.H., Das S., et al. Clinical utility gene card for: centronuclear and myotubular myopathies. Eur J Hum Genet 2012, 20.
7. Wang C.H., Dowling J.J., North K., et al. Consensus statement on standard of care for congenital myopathies. J Child Neurol 2012, 27:363-382.
8. Bevilacqua J.A., Monnier N., Bitoun M., et al. Recessive RYR1 mutations cause unusual congenital myopathy with prominent nuclear internalization and large areas of myofibrillar disorganization. Neuropathol Appl Neurobiol 2011, 37:271-284.
9. Wilmshurst J.M., Lillis S., Zhou H., et al. RYR1 mutations are a common cause of congenital myopathies with central nuclei. Ann Neurol 2010, 68:717-726.
10. Bohm J., Leshinsky-Silver E., Vassilopoulos S., et al. Samaritan myopathy, an ultimately benign congenital myopathy, is caused by a RYR1 mutation. Acta Neuropathol 2012, 124:575-581.
11. Majczenko K., Davidson A.E., Camelo-Piragua S., et al. Dominant mutation of CCDC78 in a unique congenital myopathy with prominent internal nuclei and atypical cores. Am J Hum Genet 2012, 91:365-371.
12. Parrish W.R., Stefan C.J., Emr S.D. Essential role for the myotubularin-related phosphatase Ymr1p and the synaptojanin-like phosphatases Sjl2p and Sjl3p in regulation of phosphatidylinositol 3-phosphate in yeast. Mol Biol Cell 2004, 15:3567-3579.
13. Cebollero E., van der Vaart A., Zhao M., et al. Phosphatidylinositol-3-phosphate clearance plays a key role in autophagosome completion. Curr Biol 2012, 22:1545-1553.
14. Dang H., Li Z., Skolnik E.Y., Fares H. Disease-related myotubularins function in endocytic traffic in Caenorhabditis elegans. Mol Biol Cell 2004, 15:189-196.
15. Zou W., Lu Q., Zhao D., et al. Caenorhabditis elegans myotubularin MTM-1 negatively regulates the engulfment of apoptotic cells. PLoS Genet 2009, 5:e1000679.
16. Neukomm L.J., Nicot A.S., Kinchen J.M., et al. The phosphoinositide phosphatase MTM-1 regulates apoptotic cell corpse clearance through CED-5-CED-12 in C. elegans. Development 2011, 138:2003-2014.
17. Velichkova M., Juan J., Kadandale P., et al. Drosophila Mtm and class II PI3K coregulate a PI(3)P pool with cortical and endolysosomal functions. J Cell Biol 2010, 190:407-425.
18. Dowling J.J., Vreede A.P., Low S.E., et al. Loss of myotubularin function results in T-tubule disorganization in zebrafish and human myotubular myopathy. PLoS Genet 2009, 5:e1000372.
19. Gibbs E.M., Clarke N.F., Rose K., et al. Neuromuscular junction abnormalities in DNM2-related centronuclear myopathy. J Mol Med (Berl) 2013, 91:727-737.
20. Buj-Bello A., Laugel V., Messaddeq N., et al. The lipid phosphatase myotubularin is essential for skeletal muscle maintenance but not for myogenesis in mice. Proc Natl Acad Sci USA 2002, 99:15060-15065.
21. Durieux A.C., Vignaud A., Prudhon B., et al. A centronuclear myopathy-dynamin 2 mutation impairs skeletal muscle structure and function in mice. Hum Mol Genet 2010, 19:4820-4836.
22. Pierson C.R., Dulin-Smith A.N., Durban A.N., et al. Modeling the human MTM1 p.R69C mutation in murine Mtm1 results in exon 4 skipping and a less severe myotubular myopathy phenotype. Hum Mol Genet 2012, 21:811-825.
23. Fetalvero K.M., Yu Y., Goetschkes M., et al. Defective autophagy and mTORC1 signaling in myotubularin null mice. Mol Cell Biol 2013, 33:98-110.
24. Beggs A.H., Bohm J., Snead E., et al. MTM1 mutation associated with X-linked myotubular myopathy in Labrador Retrievers. Proc Natl Acad Sci USA 2010, 107:14697-14702.
25. Al-Qusairi L., Weiss N., Toussaint A., et al. T-tubule disorganization and defective excitation-contraction coupling in muscle fibers lacking myotubularin lipid phosphatase. Proc Natl Acad Sci USA 2009, 106:18763-18768.
26. Robb S.A., Sewry C.A., Dowling J.J., et al. Impaired neuromuscular transmission and response to acetylcholinesterase inhibitors in centronuclear myopathies. Neuromuscul Disord 2011, 21:379-386.
27. Dowling J.J., Joubert R., Low S.E., et al. Myotubular myopathy and the neuromuscular junction: a novel therapeutic approach from mouse models. Dis Model Mech 2012, 5:852-859.
28. Lawlor M.W., Alexander M.S., Viola M.G., et al. Myotubularin-deficient myoblasts display increased apoptosis, delayed proliferation, and poor cell engraftment. Am J Pathol 2012, 181:961-968.
29. Hnia K., Tronchere H., Tomczak K.K., et al. Myotubularin controls desmin intermediate filament architecture and mitochondrial dynamics in human and mouse skeletal muscle. J Clin Invest 2011, 121:70-85.
30. Al-Qusairi L., Prokic I., Amoasii L., et al. Lack of myotubularin (MTM1) leads to muscle hypotrophy through unbalanced regulation of the autophagy and ubiquitin-proteasome pathways. FASEB J 2013, 27:3384-3394.
31. Romero N.B., Bitoun M. Centronuclear myopathies. Semin Pediatr Neurol 2011, 18:250-256.
32. Toussaint A., Cowling B.S., Hnia K., et al. Defects in amphiphysin 2 (BIN1) and triads in several forms of centronuclear myopathies. Acta Neuropathol 2011, 121:253-266.
33. Buj-Bello A., Fougerousse F., Schwab Y., et al. AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis. Hum Mol Genet 2008, 17:2132-2143.
34. Lawlor M.W., Armstrong D., Viola M.G., et al. Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy. Hum Mol Genet 2013, 22:1525-1538.
35. Oliveira J., Oliveira M.E., Kress W., et al. Expanding the MTM1 mutational spectrum: novel variants including the first multi-exonic duplication and development of a locus-specific database. Eur J Hum Genet 2013, 21:540-549.
36. Shichiji M., Biancalana V., Fardeau M., et al. Extensive morphological and immunohistochemical characterization in myotubular myopathy. Brain Behav 2013, 3:476-486.
37. Bevilacqua JA, Bitoun M, Biancalana V, et al. "Necklace" fibers, a new histological marker of late-onset MTM1-related centronuclear myopathy. 2009;117:283-91.
38. Trump N., Cullup T., Verheij J.B., et al. X-linked myotubular myopathy due to a complex rearrangement involving a duplication of MTM1 exon 10. Neuromuscul Disord 2012, 22:384-388.
39. Amburgey K., Lawlor M.W., Del Gaudio D., et al. Large duplication in MTM1 associated with myotubular myopathy. Neuromuscul Disord 2013, 23:214-218.
40. Mori-Yoshimura M., Okuma A., Oya Y., et al. Clinicopathological features of centronuclear myopathy in Japanese populations harboring mutations in dynamin 2. Clin Neurol Neurosurg 2012, 114:678-683.
41. Catteruccia M., Fattori F., Codemo V., et al. Centronuclear myopathy related to dynamin 2 mutations: clinical, morphological, muscle imaging and genetic features of an Italian cohort. Neuromuscul Disord 2013, 23:229-238.
42. Kierdaszuk B., Berdynski M., Karolczak J., Redowicz M.J., Zekanowski C., Kaminska A.M. A novel mutation in the DNM2 gene impairs dynamin 2 localization in skeletal muscle of a patient with late onset centronuclear myopathy. Neuromuscul Disord 2013, 23:219-228.
43. Bitoun M., Bevilacqua J.A., Prudhon B., et al. Dynamin 2 mutations cause sporadic centronuclear myopathy with neonatal onset. Ann Neurol 2007, 62:666-670.
44. Bitoun M., Maugenre S., Jeannet P.Y., et al. Mutations in dynamin 2 cause dominant centronuclear myopathy. Nat Genet 2005, 37:1207-1209.
45. Koutsopoulos O.S., Kretz C., Weller C.M., et al. Dynamin 2 homozygous mutation in humans with a lethal congenital syndrome. Eur J Hum Genet 2013, 21:637-642.
46. Nicot A.S., Toussaint A., Tosch V., et al. Mutations in amphiphysin 2 (BIN1) disrupt interaction with dynamin 2 and cause autosomal recessive centronuclear myopathy. Nat Genet 2007, 39:1134-1139.
47. Claeys K.G., Maisonobe T., Bohm J., et al. Phenotype of a patient with recessive centronuclear myopathy and a novel BIN1 mutation. Neurology 2010, 74:519-521.
48. Herman G.E., Finegold M., Zhao W., de Gouyon B., Metzenberg A. Medical complications in long-term survivors with X-linked myotubular myopathy. J Pediatr 1999, 134:206-214.
49. Jungbluth H., Sewry C.A., Muntoni F. Core myopathies. Semin Pediatr Neurol 2011, 18:239-249.
50. Zhou H., Rokach O., Feng L., et al. RyR1 deficiency in congenital myopathies disrupts excitation-contraction coupling. Hum Mutat 2013, 34:986-996.
51. Bohm J., Vasli N., Malfatti E., et al. An integrated diagnosis strategy for congenital myopathies. PLoS One 2013, 8:e67527.
52. Ceyhan O, Agrawal P, Hidalgo C, et al. Recessive truncating titin gene (TTN) mutations in patients presenting with centronuclear myopathy. Neurology 2013; in press.
53. Herman D.S., Lam L., Taylor M.R., et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012, 366:619-628.
54. Durieux A.C., Vassilopoulos S., Laine J., et al. A centronuclear myopathy-dynamin 2 mutation impairs autophagy in mice. Traffic 2012, 13:869-879.
55. Dowling J.J., Low S.E., Busta A.S., Feldman E.L. Zebrafish MTMR14 is required for excitation-contraction coupling, developmental motor function and the regulation of autophagy. Hum Mol Genet 2010, 19:2668-2681.
56. Gibbs E.M., Davidson A.E., Trickey-Glassman A., et al. Two dynamin-2 genes are required for normal zebrafish development. PLoS One 2013, 8:e55888.
57. Hirata H., Watanabe T., Hatakeyama J., et al. Zebrafish relatively relaxed mutants have a ryanodine receptor defect, show slow swimming and provide a model of multi-minicore disease. Development 2007, 134:2771-2781.
58. Dowling J.J., Arbogast S., Hur J., et al. Oxidative stress and successful antioxidant treatment in models of RYR1-related myopathy. Brain 2012, 135:1115-1127.
59. Joubert R., Vignaud A., Le M., Moal C., Messaddeq N., Buj-Bello A. Site-specific Mtm1 mutagenesis by an AAV-Cre vector reveals that myotubularin is essential in adult muscle. Hum Mol Genet 2013, 22:1856-1866.
60. Pele M., Tiret L., Kessler J.L., Blot S., Panthier J.J. SINE exonic insertion in the PTPLA gene leads to multiple splicing defects and segregates with the autosomal recessive centronuclear myopathy in dogs. Hum Mol Genet 2005, 14:1417-1427.
61. Maurer M., Mary J., Guillaud L., et al. Centronuclear myopathy in Labrador retrievers: a recent founder mutation in the PTPLA gene has rapidly disseminated worldwide. PLoS One 2012, 7:e46408.
62. Bohm J., Vasli N., Maurer M., et al. Altered splicing of the BIN1 muscle-specific exon in humans and dogs with highly progressive centronuclear myopathy. PLoS Genet 2013, 9:e1003430.
63. Lujan Feliu-Pascual A., Shelton G.D., Targett M.P., et al. Inherited myopathy of great Danes. J Small Anim Pract 2006, 47:249-254.
64. Davies S.E., Davies D.R., Richards R.B., Bruce W.J. Inherited myopathy in a Great Dane. Aust Vet J 2008, 86:43-45.
65. Amoasii L., Bertazzi D.L., Tronchere H., et al. Phosphatase-dead myotubularin ameliorates X-linked centronuclear myopathy phenotypes in mice. PLoS Genet 2012, 8:e1002965.
66. Amoasii L., Hnia K., Chicanne G., et al. Myotubularin and PtdIns3P remodel the sarcoplasmic reticulum in muscle in vivo. J Cell Sci 2013, 126:1806-1819.
67. Gupta V.A., Hnia K., Smith L.L., et al. Loss of catalytically inactive lipid phosphatase myotubularin-related protein 12 impairs myotubularin stability and promotes centronuclear myopathy in zebrafish. PLoS Genet 2013, 9:e1003583.